EMA adopts guideline on biosimilar monoclonal antibodies

Home/Guidelines | Posted 11/02/2011

EMA announced on its website that it has adopted the long-anticipated guideline on biosimilar monoclonal antibodies.

India regulatory authority to adopt CTD format for NDAs

Home/Guidelines | Posted 11/02/2011

On 28 October 2010, India’s Central Drugs Standard Control Organization (CDSCO) released new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.

The FDA’s 2010 final rule and draft guidance

Home/Guidelines | Posted 04/02/2011

In an effort to improve safety detection, the FDA issued a final rule and draft guidance on 29 September 2010 to clarify the requirements governing safety reporting requirements for human drug and biological products subject to an investigational new drug (IND) application.

EGA meeting London 2010: monoclonal antibodies and biosimilars guidelines

Home/Guidelines | Posted 10/09/2010

In his opening address to the 8th EGA International Symposium on Biosimilar Medicines held in London on 2–3 September 2010, EGA Director General Mr Greg Perry praised the EU for inspiring the rest of the world regarding development of biosimilar guidelines.

The current EU regulatory framework governing biosimilars

Home/Guidelines | Posted 25/08/2010

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has guidelines that provide a framework for the development of ‘biosimilars’ in the EU. The recent licensing of recombinant somatropins and several erythropoietins has proved that the present system works. Can the same regulatory path also be applied to more complex biologicals, such as monoclonal antibodies (mAbs)?

FDA Form 483 – punishment or learning opportunity?

Home/Guidelines | Posted 10/08/2010

The US FDA is authorised to perform inspections under the Federal Food, Drug, and Cosmetic Act. The FDA Form 483 is a form used by the FDA to document and communicate concerns discovered during these inspections and to list items that deviate from Good Manufacturing Practices.

Licensing of biosimilars in Europe

Home/Guidelines | Posted 02/07/2010

How is licensing of biosimilars actually being applied in Europe? This was the question broached in a paper by Dr Christian Schneider – Chairman of both the Committee for Advanced Therapies and Biosimilar Medicinal Products Working Party and Co-opted member of the Committee for Medicinal Products for Human Use (CHMP).

Singapore outlines process to register biosimilars

Home/Guidelines | Posted 16/10/2009

Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Comparability studies between the biosimilar product and its reference product also must be submitted, the Health Sciences Authority says in the guidance posted on its website on 1 August 2009.

Regulatory reflections on the FDA’s guidance on biosimilars and follow-on branded biologics

Home/Guidelines | Posted 05/10/2009

With US Congressional actions on biosimilar/follow-on biologics approaching, the FDA has issued a Guidance regarding the use of pens, jets, and other related injectors (see Draft Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet and Related Injectors Intended for Use with Drugs and Biological Products, April 2009). The Guidance recognises that these are innovative approaches to deliver drugs or biologics products that may enhance accuracy and patient compliance.

Global biosimilars guideline development – EGA’s perspective

Home/Guidelines | Posted 28/09/2009

Biosimilar guidelines and regulations are being developed all over the world, as outlined at the 7th EGA Annual Symposium on Biosimilars recently held in London, UK by Ingrid Schwarzenberger, Head Regulatory Affairs Biopharmaceuticals at Sandoz and member of European Generic medicines Association’s (EGA) European Biopharmaceutical Group.